<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922812462235</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922812462235</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Moderate Dose Inhaled Corticosteroid-Induced Symptomatic Adrenal Suppression</article-title>
<subtitle>Case Report and Review of the Literature</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Schwartz</surname><given-names>Richard H.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922812462235">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Neacsu</surname><given-names>Otilia</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922812462235">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ascher</surname><given-names>David P.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922812462235">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Alpan</surname><given-names>Oral</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922812462235">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922812462235"><label>1</label>Inova Fairfax Hospital for Children, Falls Church, VA, USA</aff>
<author-notes>
<corresp id="corresp1-0009922812462235">Richard H. Schwartz, 100 East Street, SE, Suite 301, Vienna, VA 22180, USA Email: <email>rhs738@aol.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>51</volume>
<issue>12</issue>
<fpage>1184</fpage>
<lpage>1190</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Inhaled corticosteroids (ICS) are drugs of choice for persistent asthma. Less than 500 µg/d of fluticasone are believed to be safe. We found 92 cases of adrenal suppression in PubMed; among these cases there were 13 children who took 500 µg/d or less of fluticasone. Adrenal insufficiency was diagnosed in a 7-year-old boy on 460 µg ICS for 16 months, with a diagnosis of chronic persistent asthma. A random cortisol was nondetectable as was an early morning cortisol. ICS have greatly improved the day-to-day lives of children with chronic persistent asthma. Parents of children younger than 12 years, who use at least 400 µg of inhaled fluticasone (or bioequivalent), must be given oral and written instructions about warning symptoms of hypocortisolism. Major stress such as surgery, gastrointestinal, bronchopulmonary, or other systemic infections, and heat stress may mandate a written plan of action for use by hospital physicians.</p>
</abstract>
<kwd-group>
<kwd>adrenal suppression</kwd>
<kwd>adrenal insufficiency</kwd>
<kwd>fluticasone</kwd>
<kwd>bronchial asthma</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0009922812462235" sec-type="intro">
<title>Introduction</title>
<p>Guidelines from many countries advocate the use of inhaled corticosteroids for the management of persistent asthma. Inhaled corticosteroid medications, administered either by metered-dose inhaler or as a dry powder, are drugs of choice in Canada, the United Kingdom, and the United States for the management of chronic mild or moderate persistent asthma.<sup><xref ref-type="bibr" rid="bibr1-0009922812462235">1</xref><xref ref-type="bibr" rid="bibr2-0009922812462235"/>-<xref ref-type="bibr" rid="bibr3-0009922812462235">3</xref></sup> GlaxoSmithKline, manufacturer of Advair HFA 115/21, states clearly in the package insert that
<disp-quote>
<p>the product is indicated for the treatment of asthma in patients aged 12-years and older because it has not been studied in younger children. The usual starting dose for patients 12 years and older is 2 puffs, twice daily for a total daily fluticasone dose of 460 µg. No dosage instructions are given for younger children, even though the product is probably commonly prescribed by allergy and pulmonary medicine specialists for that age group. Patients should be maintained on the lowest strength of ADVAIR HFA™ that effectively controls their asthma. It is possible that systemic corticosteroid effects such as adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when fluticasone propionate is administered at higher than recommended doses over prolonged periods of time.</p>
</disp-quote></p>
<p>The Australian-approved dose of inhaled fluticasone for children is only100 to 200 µg daily.<sup><xref ref-type="bibr" rid="bibr4-0009922812462235">4</xref></sup> The Canadian Asthma Consensus report states that the minimum age for administration of fluticasone by metered-dose inhaler and spacer is 12 months, at a daily dose of 200 to 250 µg.<sup><xref ref-type="bibr" rid="bibr5-0009922812462235">5</xref></sup> There is no US recommendation for a starting dose for children younger than 12 years, leaving physicians, nurse practitioners, and physician assistants to dose without guidance and often close to the recommended dose for individuals 12 years and older (off-label use).</p>
<p>A meta-analysis of trials of fluticasone in adolescents (&gt;12 years) and adults using inhaled corticosteroids over time found that maximal efficacy was achieved at doses around 500 µg/d, <italic>but 90% of the benefit was achieved at doses of 100 to 250 µg/day</italic>.<sup><xref ref-type="bibr" rid="bibr6-0009922812462235">6</xref></sup> Fluticasone is among the most widely prescribed inhaled corticosteroid medications. High-potency corticosteroids such as fluticasone propionate or mometasone furoate should be given at the lowest possible dose. High doses are associated with an increased risk of adrenal suppression. Daily doses of 200 µg achieve 90% of the efficacy of high doses.<sup><xref ref-type="bibr" rid="bibr7-0009922812462235">7</xref>,<xref ref-type="bibr" rid="bibr8-0009922812462235">8</xref></sup> Masoli et al<sup><xref ref-type="bibr" rid="bibr8-0009922812462235">8</xref></sup> and the British guidelines<sup><xref ref-type="bibr" rid="bibr2-0009922812462235">2</xref></sup> state that the dose–response to fluticasone propionate appears to plateau between 100 and 200 µg/d. When higher daily doses of fluticasone are used for short periods, the dose should be reduced back to 0.2 mg (200 µg) as soon as possible (step-down dosing).</p>
<p>Conclusions from a 2006 review<sup><xref ref-type="bibr" rid="bibr9-0009922812462235">9</xref></sup> of adverse effects of inhaled corticosteroids stated, “In the majority of patients with mild to moderate asthma, clinically relevant adverse effects on growth or cortisol levels are absent.” In that same year, White et al<sup><xref ref-type="bibr" rid="bibr10-0009922812462235">10</xref></sup> studied 45 children who were inhaling fluticasone propionate (mean dose 745 µg for 19 months). Few of those children taking low doses had suppression of early morning cortisol or abnormal ACTH (adrenocorticotropic hormone) stimulation test cortisol results. However, 10 of the 28 children who took high-dose fluticasone had both low morning cortisol levels and abnormal post–ACTH stimulation cortisol levels.<sup><xref ref-type="bibr" rid="bibr10-0009922812462235">10</xref></sup></p>
<p>There are no current recommendations to routinely evaluate patients for adrenal suppression by obtaining an early morning cortisol screening test on those patients who had been on moderate- or high-dose inhaled corticosteroid medication. As of 2006, 60 cases of adrenal suppression were reported in the medical literature.<sup><xref ref-type="bibr" rid="bibr7-0009922812462235">7</xref>,<xref ref-type="bibr" rid="bibr11-0009922812462235">11</xref></sup> We found an additional 32 cases in the medical literature since 2006. Many of the patients with adrenal suppression had symptomatic adrenal insufficiency with chronic fatigue, poor endurance, weakness, hypoglycemia, and rarely, mental confusion. When coupled with major physiologic stress such as surgery, infection, trauma, or dehydration, adrenal insufficiency may lead to a life-threatening condition ending in cardiovascular collapse, myocardial failure, or overwhelming sepsis.<sup><xref ref-type="bibr" rid="bibr12-0009922812462235">12</xref></sup> Chronic use of fluticasone propionate in high doses (&gt;0.75 mg/d) has caused not only adrenal insufficiency but also severe adrenal crisis leading to death.<sup><xref ref-type="bibr" rid="bibr13-0009922812462235">13</xref>,<xref ref-type="bibr" rid="bibr14-0009922812462235">14</xref></sup></p>
<p>Our literature search was able to locate 13 children who developed symptomatic adrenal insufficiency from a daily dose of 500 µg or less (see “Discussion” section). Fluticasone propionate is much more likely to cause clinically symptomatic adrenal suppression than most other inhaled corticosteroids such as beclomethasone diproprionate,<sup><xref ref-type="bibr" rid="bibr15-0009922812462235">15</xref></sup> triamcinolone acetonide, or budes onide.<sup><xref ref-type="bibr" rid="bibr14-0009922812462235">14</xref>,<xref ref-type="bibr" rid="bibr16-0009922812462235">16</xref></sup> Health Canada database reported 9 cases of adrenal insufficiency due to inhaled corticosteroids from 1996 to 2002. All were associated with the use of fluticasone.<sup><xref ref-type="bibr" rid="bibr17-0009922812462235">17</xref></sup></p>
</sec>
<sec id="section2-0009922812462235">
<title>Reasons for Adrenocortical Suppression</title>
<p>Adrenal insufficiency, occult or overt, may result from abrupt discontinuation of moderate-dose inhaled corticosteroid use, forgetting to pack the inhaled corticosteroid before departure for summer vacation, or from abrupt noncompliance during chronic treatment. The majority of children with proven adrenal suppression secondary to inhaled corticosteroids appear to be asymptomatic, at least in the nonstressed state.</p>
<p>All the above may lead to acute steroid deficiency and life-threatening cardiovascular collapse when coupled with major physiologic stress. The adrenal glands are slow to recover, and cortisol insufficiency can still be detected by provocative testing more than 1 year later.<sup><xref ref-type="bibr" rid="bibr11-0009922812462235">11</xref></sup></p>
</sec>
<sec id="section3-0009922812462235" sec-type="cases">
<title>Case Report</title>
<p>The following case report describes profound chronic adrenal suppression in a 7-year-old boy who presented with moderate persistent asthma, chronic fatigue, and decreased endurance. His mother related that after a few months of taking inhaled corticosteroid for control of persistent asthma, he could barely keep up with his peers during play and sports. The patient was taking fluticasone daily at a dose of 2 inhalations, twice daily, in a fixed combination with salmeterol/fluticasone (Advair 115 µg of fluticasone propionate and 21 µg of salmeterol in a hydrofluoralkane [HFA] metered dose inhaler) administered through a valved spacer with mouthpiece. He also received treatment for allergic rhinitis with fluticasone furoate nasal spray 55 µg/d, once daily, for a total daily dose of 0.515 mg (515 µg) per day of fluticasone.</p>
<p>During the next 12 months, he visited his allergy specialist and primary care pediatrician many times for recurrent upper respiratory infections that were diagnosed and treated as recurrent sinusitis or and bronchitis. During these visits, his mother repeated often, that her son seemed uncommonly fatigued at play and complained of chronic, albeit not incapacitating, headaches. In addition to taking maintenance inhaled corticosteroid and intranasal steroid, the boy required 2 short courses of oral prednisolone for exacerbation of bronchial asthma but neither of these was recent. There were no life-threatening attacks of bronchial asthma, no visits to an emergency medicine facility, and no hospital admissions. Over the 2 months prior to the correct diagnosis, the child was evaluated by pediatric immunologist, an allergist, and a pediatric infectious disease specialist. His behavior and academic performance at school were unremarkable. Physical exam revealed a pale-looking boy with a blood pressure of 56/48 mm Hg. His weight was at the 50th percentile for weight, 75th percentile for height, and body surface area of 0.95/1.72 m<sup>2</sup>. He was prepubertal and had an otherwise unremarkable physical exam, with no evidence of hyperpigmentation.</p>
<p>Tests for hematological disease, immunologic deficiencies, and infectious diseases associated with chronic fatigue and frequent upper respiratory infections, along with a random cortisol were ordered. Results of the complete blood count included a total leukocyte count of 5800 cells with the following differential results: neutrophils = 44%, lymphocytes = 44%, eosinophils = 1%, and monocytes = 11%. The sedimentation rate was 13 mm/h (normal). Immunoglobulins IgA, IgM, and IgG were within the normal range and serological tests for Lyme disease, infectious mononucleosis not detectable.</p>
<p>A random cortisol was undetectable, which prompted referral to endocrine clinic. Further workup confirmed undetectable 8 AM fasting cortisol (below 1 µg/dL) along with a decreased ACTH 5 pg/mL (normal between 9 and 57 pg/mL). His basic metabolic profile had normal results: sodium of 141, potassium 4.3, bicarbonate of 23 mmol/L, and a glucose of 70. His plasma renin activity was 2.38 ng/m, which is in the normal range. Anti-adrenal antibodies and 21-hydroxylase antibodies were not detectable and thyroid function test results were normal (thyroid-stimulating hormone and free T4). Results of adrenal gland hormones were not consistent with primary adrenal insufficiency, for example, Addison disease or X-linked adrenoleukodystrophy, which are characterized by low cortisol but high, not low, ACTH.</p>
<p>A presumptive diagnosis of iatrogenic hypocortisolism secondary to chronic use of inhaled corticosteroids (moderate dose) was made. The child’s slight build, body surface area of 0.95/m<sup>2</sup> was thought to have contributed to his unexpected adrenal suppression from a daily dose of fluticasone less than 500 µg.</p>
<p>Cortisol replacement at 10 mg hydrocortisone/m<sup>2</sup>/d was ordered immediately after the test results were reviewed by the boy’s endocrinologist. There was no improvement for several weeks, after which, the fatigue and diminished endurance slowly resolved.</p>
</sec>
<sec id="section4-0009922812462235" sec-type="discussion">
<title>Discussion</title>
<p>Published guidelines from the United Kingdom, the United States, Canada, and other countries state that inhaled corticosteroids, as excellent modifiers of the inflammatory process, are the drugs of choice for the management and maintenance of moderate or severe persistent bronchial asthma.<sup><xref ref-type="bibr" rid="bibr1-0009922812462235">1</xref><xref ref-type="bibr" rid="bibr2-0009922812462235"/>-<xref ref-type="bibr" rid="bibr3-0009922812462235">3</xref></sup> Inhaled corticosteroids reduce symptoms in children with asthma, improve quality of life in asthmatic children and their families, decrease absences from school and work, reduce airway inflammation, and improve lung function and bronchial responsiveness.<sup><xref ref-type="bibr" rid="bibr18-0009922812462235">18</xref></sup></p>
<sec id="section5-0009922812462235">
<title>Fluticasone Propionate: Major Cause of Adrenal Suppression</title>
<p>Pharmacodynamics is important to understand the absorption of inhaled fluticasone propionate. In a study for the National Heart Lung and Blood Institute’s Asthma Clinical Research Network, using plasma cortisol area under the curve, a dosage of fluticasone propionate of only 0.35 mg (352 µg) per day produced 50% adrenal suppression.<sup><xref ref-type="bibr" rid="bibr19-0009922812462235">19</xref>,<xref ref-type="bibr" rid="bibr20-0009922812462235">20</xref></sup> The half-life of fluticasone is by far the longest of the inhaled corticosteroids.</p>
<p>Current recommendations from investigators in adrenal suppression from inhaled corticosteroids state that children on daily maintenance therapy should not exceed 400 µg of fluticasone or bioequivalent.<sup><xref ref-type="bibr" rid="bibr21-0009922812462235">21</xref>,<xref ref-type="bibr" rid="bibr22-0009922812462235">22</xref></sup> In the past, it was believed that inhaled fluticasone was deactivated in the liver rapidly and as such, did not have systemic effects in daily doses lower than 750 µg. We have now learned that chronic use of moderate- to- high-dose high-potency inhaled corticosteroids may lead to adrenal suppression.<sup><xref ref-type="bibr" rid="bibr4-0009922812462235">4</xref>,<xref ref-type="bibr" rid="bibr13-0009922812462235">13</xref>,<xref ref-type="bibr" rid="bibr18-0009922812462235">18</xref>,<xref ref-type="bibr" rid="bibr23-0009922812462235">23</xref><xref ref-type="bibr" rid="bibr24-0009922812462235"/><xref ref-type="bibr" rid="bibr25-0009922812462235"/><xref ref-type="bibr" rid="bibr26-0009922812462235"/><xref ref-type="bibr" rid="bibr27-0009922812462235"/><xref ref-type="bibr" rid="bibr28-0009922812462235"/><xref ref-type="bibr" rid="bibr29-0009922812462235"/><xref ref-type="bibr" rid="bibr30-0009922812462235"/><xref ref-type="bibr" rid="bibr31-0009922812462235"/><xref ref-type="bibr" rid="bibr32-0009922812462235"/><xref ref-type="bibr" rid="bibr33-0009922812462235"/><xref ref-type="bibr" rid="bibr34-0009922812462235"/><xref ref-type="bibr" rid="bibr35-0009922812462235"/>-<xref ref-type="bibr" rid="bibr36-0009922812462235">36</xref></sup> The majority of children with proven adrenal suppression secondary to inhaled corticosteroids appear to be asymptomatic, at least in the nonstressed state. Neither hyponatremia nor hyperkalemia are detected in iatrogenic adrenal insufficiency secondary to inhaled corticosteroids because mineralocorticoid secretion remains unimpaired.<sup><xref ref-type="bibr" rid="bibr12-0009922812462235">12</xref></sup> Hyperpigmentation is absent in iatrogenic adrenal suppression because ACTH and melanocyte stimulating hormone production are normal.</p>
<p>We have counted more than 92 cases of adrenal suppression in our review of the medical literature; most of them were in children who were taking adult doses of inhaled corticosteroids. Among those 92 cases, we located 13 cases of adrenal suppression in children with daily doses of inhaled fluticasone propionate at or lower than 500 µg (<xref ref-type="table" rid="table1-0009922812462235">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr11-0009922812462235">11</xref>,<xref ref-type="bibr" rid="bibr14-0009922812462235">14</xref>,<xref ref-type="bibr" rid="bibr21-0009922812462235">21</xref>,<xref ref-type="bibr" rid="bibr22-0009922812462235">22</xref>,<xref ref-type="bibr" rid="bibr36-0009922812462235">36</xref><xref ref-type="bibr" rid="bibr37-0009922812462235"/><xref ref-type="bibr" rid="bibr38-0009922812462235"/>-<xref ref-type="bibr" rid="bibr39-0009922812462235">39</xref></sup> Many of those children had arcane symptoms of chronic adrenal insufficiency.</p>
<table-wrap id="table1-0009922812462235" position="float">
<label>Table 1.</label>
<caption>
<p>Literature Review of 13 Children Who Developed Adrenal Suppression From Low-Dose (≤500 µg) Daily Fluticasone</p>
</caption>
<graphic alternate-form-of="table1-0009922812462235" xlink:href="10.1177_0009922812462235-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Reference</th>
<th align="center">No. of Children</th>
<th align="center">Dose (µg)</th>
<th align="center">Test Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian Adverse Drug Reactions Bulletin<sup><xref ref-type="bibr" rid="bibr4-0009922812462235">4</xref></sup></td>
<td>1</td>
<td>250</td>
<td>×<sup><xref ref-type="table-fn" rid="table-fn1-0009922812462235">a</xref></sup></td>
</tr>
<tr>
<td/>
<td>1</td>
<td>500</td>
<td>×<sup><xref ref-type="table-fn" rid="table-fn1-0009922812462235">a</xref></sup></td>
</tr>
<tr>
<td>Patel and Clayton<sup><xref ref-type="bibr" rid="bibr21-0009922812462235">21</xref></sup></td>
<td>1</td>
<td>&lt;500</td>
<td>Basal morning cortisol, Synacthen test</td>
</tr>
<tr>
<td>Barton<sup><xref ref-type="bibr" rid="bibr17-0009922812462235">17</xref></sup></td>
<td>1</td>
<td>250</td>
<td>×<sup><xref ref-type="table-fn" rid="table-fn1-0009922812462235">a</xref></sup></td>
</tr>
<tr>
<td>Paton et al<sup><xref ref-type="bibr" rid="bibr22-0009922812462235">22</xref></sup></td>
<td>4</td>
<td>×<sup><xref ref-type="table-fn" rid="table-fn1-0009922812462235">a</xref></sup></td>
<td>×<sup><xref ref-type="table-fn" rid="table-fn1-0009922812462235">a</xref></sup></td>
</tr>
<tr>
<td>Dorsey et al<sup><xref ref-type="bibr" rid="bibr36-0009922812462235">36</xref></sup></td>
<td>1</td>
<td>250</td>
<td>Synacthen test, dehydroepiandrosterone sulfate (DHEA-S)</td>
</tr>
<tr>
<td>Molimard et al<sup><xref ref-type="bibr" rid="bibr37-0009922812462235">37</xref></sup></td>
<td>1</td>
<td>250</td>
<td>Basal morning cortisol, Synacthen test, 24-hour urinary free-cortisol</td>
</tr>
<tr>
<td>Heller et al<sup><xref ref-type="bibr" rid="bibr38-0009922812462235">38</xref></sup></td>
<td>1</td>
<td>500</td>
<td>Basal morning cortisol</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>250</td>
<td>Basal morning cortisol</td>
</tr>
<tr>
<td>Santiago and Ratzan<sup><xref ref-type="bibr" rid="bibr39-0009922812462235">39</xref></sup></td>
<td>1</td>
<td>220</td>
<td>Basal morning cortisol, Synacthen test</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0009922812462235">
<label>a</label>
<p>No test results recorded in reference.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Our opinion echoes that of others. Pediatric doses 400 µg or greater, should be administered for as brief a time as possible, preferably less than 6 weeks. As soon as the asthma has been stabilized for a several weeks, the daily dose should be reduced gradually to 200 µg.<sup><xref ref-type="bibr" rid="bibr21-0009922812462235">21</xref>,<xref ref-type="bibr" rid="bibr22-0009922812462235">22</xref></sup></p>
</sec>
<sec id="section6-0009922812462235">
<title>Idiosyncratic Response to Inhaled Fluticasone</title>
<p>Why do a small minority of children inhaling fluticasone in recommended daily doses for optimal control of moderate or severe bronchial asthma have no adrenal suppression, others have occult adrenal suppression, and a tiny minority have symptomatic adrenal suppression? Nonstress symptoms of occult chronic adrenal suppression include reduction of growth velocity over time, fatigue, poor endurance and susceptibility to respiratory and gastrointestinal infections. An even smaller percentage of children with adrenal suppression suffer from hypoglycemia and Addisonian crisis.<sup><xref ref-type="bibr" rid="bibr28-0009922812462235">28</xref></sup> There are several reasons for this phenomenon, including individual differences in sensitivity to inhaled corticosteroids. For example, Pearce and Mabin<sup><xref ref-type="bibr" rid="bibr40-0009922812462235">40</xref></sup> state that individuals have differing sensitivities to inhaled corticosteroids. Our patient teaches us that idiosyncratic responses to inhaled corticosteroids may occur.<sup><xref ref-type="bibr" rid="bibr21-0009922812462235">21</xref></sup> Smith et al<sup><xref ref-type="bibr" rid="bibr41-0009922812462235">41</xref></sup> suggests that all inhaled corticosteroids have the potential for adrenal suppression, not only high potency fluticasone or mometasone.</p>
<p>Possible additional reasons for adrenal suppression with moderate doses of inhaled corticosteroid medication include the following: protracted chronic continuous use of the drug, particularly when a high potency drug is used such as fluticasone propionate (2× potency compared with budesonide); using much more than the prescribed dose (we verified that this was not the cause for our patient, according to actual pharmacy records); combined use of inhaled fluticasone and intranasal corticosteroid (as exemplified by our patient); use of continuous moderate dose instead of low dose in infants and toddlers; and swallowing some of the larger particle size of the medication. We agree with the recommendation to step-down any moderate or high dose of inhaled steroid dose within a few weeks after asthma symptoms are controlled.</p>
</sec>
<sec id="section7-0009922812462235">
<title>When to Test for Adrenal Suppression</title>
<p>When should the physician who is managing a child taking inhaled fluticasone or other corticosteroids for chronic persistent bronchial asthma consider ordering a test for cortisol insufficiency?</p>
<p>Acknowledging that millions of children take inhaled corticosteroids for long term for control of bronchial asthma and that clinically significant adrenal suppression is uncommon, we suggest a mandatory screening test of early morning cortisol under the circumstances listed in <xref ref-type="table" rid="table2-0009922812462235">Tables 2</xref> and <xref ref-type="table" rid="table3-0009922812462235">3</xref>.</p>
<table-wrap id="table2-0009922812462235" position="float">
<label>Table 2.</label>
<caption>
<p>Signs and Symptoms of Adrenal Insufficiency</p>
</caption>
<graphic alternate-form-of="table2-0009922812462235" xlink:href="10.1177_0009922812462235-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>1. Fatigue (chronic)</td>
</tr>
<tr>
<td>2. Endurance below expectation</td>
</tr>
<tr>
<td>3. Weakness</td>
</tr>
<tr>
<td>4. Vomiting recurrently</td>
</tr>
<tr>
<td>5. Weight loss without dieting</td>
</tr>
<tr>
<td>6. Hypoglycemia</td>
</tr>
<tr>
<td>7. Heat intolerance</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table3-0009922812462235" position="float">
<label>Table 3.</label>
<caption>
<p>When to Consider Laboratory Assessment for Adrenocortical Suppression</p>
</caption>
<graphic alternate-form-of="table3-0009922812462235" xlink:href="10.1177_0009922812462235-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>1. The dose of fluticasone is at least twice the recommended dose of 0.2 mg (200 µg) per day, for 3 continuous months or more</td>
</tr>
<tr>
<td>2. Has multiple respiratory infections (bronchitis, acute paranasal sinusitis, clinical pneumonia), requiring many office visits to a physician/nurse practitioner</td>
</tr>
<tr>
<td>3. Difficulty fighting such infections so that he or she usually requires more than 3 or 4 days to improve</td>
</tr>
<tr>
<td>4. Chronic complaints of poor endurance, stamina, or documented fatigue or weakness</td>
</tr>
<tr>
<td>5. Diminished body surface area for age</td>
</tr>
<tr>
<td>6. Growth suppression (nonspecific sign of chronic adrenal suppression)</td>
</tr>
<tr>
<td>7. Serious injury</td>
</tr>
<tr>
<td>8. Nontrivial infection, pneumonia, and influenza virus infection, or deep abscess—or has undergone major surgery or has other conditions where insufficiency of cortisol can cause adrenal crisis</td>
</tr>
<tr>
<td>9. Symptomatic hypoglycemia</td>
</tr>
<tr>
<td>10. Gastroenteritis with dehydration</td>
</tr>
<tr>
<td>11. Heat stress</td>
</tr>
<tr>
<td>12. Chronic nausea and or vomiting</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section8-0009922812462235">
<title>Laboratory Measurement of Adrenal Suppression</title>
<p>The test of choice to assess adrenal suppression is an early morning serum cortisol. The currently recommended next step is a low-dose synacthin stimulation test.<sup><xref ref-type="bibr" rid="bibr16-0009922812462235">16</xref>,<xref ref-type="bibr" rid="bibr42-0009922812462235">42</xref></sup> Dihydroepiandrosterone sulfate, a metabolic marker of adrenal androgen production is not widely recommended by pediatric endocrinologists as a screening test for iatrogenic adrenal suppression.<sup><xref ref-type="bibr" rid="bibr36-0009922812462235">36</xref>,<xref ref-type="bibr" rid="bibr43-0009922812462235">43</xref></sup> A corticotrophin-releasing hormone test may be recommended by a pediatric endocrinologist in certain circumstances.<sup><xref ref-type="bibr" rid="bibr44-0009922812462235">44</xref></sup> More complex tests are best supervised by a pediatric endocrinologist.<sup><xref ref-type="bibr" rid="bibr45-0009922812462235">45</xref><xref ref-type="bibr" rid="bibr46-0009922812462235"/>-<xref ref-type="bibr" rid="bibr47-0009922812462235">47</xref></sup> An 8 <sc>am</sc> intravenous administration of 1 µg cosyntropin or 500 nmol/L, although controversial, may be the next step to diagnose adrenal suppression secondary to inhaled fluticasone. In the performance of this test, serum cortisol is obtained at baseline and T-30 minutes. A peak serum cortisol &gt;0.5 mg (500 µg) is considered a normal response. This test is said to have a specificity and sensitivity for identification of adrenal suppression of approximately 90% each. A meta-analysis of tests concluded that the low-dose corticotropin test was superior to standard-dose test for diagnosing chronic hypothalamic–pituitary–adrenal insufficiency.<sup><xref ref-type="bibr" rid="bibr48-0009922812462235">48</xref></sup></p>
</sec>
</sec>
<sec id="section9-0009922812462235" sec-type="conclusions">
<title>Conclusion</title>
<p>The US Food and Drug Administration and the pharmaceutical companies that manufacture high-potency inhaled corticosteroids must correct the orphan drug status of these drugs, at the very least, when used for children younger than 12 years. Inhaled corticosteroids should be taken at the lowest effective dose, dosing should be reviewed regularly by the medical provider, and should not be discontinued abruptly. We suggest that the canister for such children contain no more than 44 µg/puff of fluticasone or equipotent inhaled corticosteroid. There are lessons to be learned from our 7-year-old patient, the 14th patient reported with adrenal suppression from a moderate daily dose (500 µg fluticasone propionate) for 16 months. This dose, acceptable for an average 12-year-old caused severe chronic cortisol depletion, with symptoms of chronic fatigue, poor endurance, headaches, and weakness. Physicians who prescribe inhaled corticosteroids in excess of 400 µg per day for preadolescent children should order quarterly tests for early morning cortisol levels. Physicians and parents must be educated to anticipate prompt management of such children when they undergo periods of serious physiologic stress.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922812462235">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Becker</surname><given-names>A</given-names></name>
<name><surname>Lemière</surname><given-names>C</given-names></name>
<name><surname>Bérubé</surname><given-names>D</given-names></name>
<etal/></person-group>; <collab>Asthma Guidelines Working Group of the Canadian Network For Asthma Care</collab>. <article-title>Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003</article-title>. <source>CMAJ</source>. <year>2005</year>;<volume>173</volume>(<supplement>6 suppl</supplement>):<fpage>S3</fpage>-<lpage>S11</lpage>.</citation>
</ref>
<ref id="bibr2-0009922812462235">
<label>2.</label>
<citation citation-type="web"><collab>British Thoracic Society, Scottish Intercollegiate Guidelines Network</collab>. <source>British Guideline on the Management of Asthma: Quick Reference Guide</source>. <year>2008</year>, <access-date>revised May 2011</access-date>. <ext-link ext-link-type="uri" xlink:href="http://www.sign.ac.uk/pdf/qrg101.pdf">http://www.sign.ac.uk/pdf/qrg101.pdf</ext-link>. <access-date>Accessed September 14, 2012</access-date>.</citation>
</ref>
<ref id="bibr3-0009922812462235">
<label>3.</label>
<citation citation-type="book"><collab>National Asthma Education and Prevention Program Expert Panel</collab>. <source>Report 3: Guidelines for the Diagnosis and Management of Asthma</source> (NIH publication 08-4051). <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>National Heart, Lung, and Blood Institute, US Department of Health and Human Services</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr4-0009922812462235">
<label>4.</label>
<citation citation-type="gov"><collab>Fluticasone and adrenal crisis</collab>. <source>Australian Adverse Drug Reactions Bulletin</source>. <year>2003</year>;<volume>22</volume>:<fpage>2</fpage>. <ext-link ext-link-type="uri" xlink:href="http://www.tga.gov.au/pdf/aadrb-0304.pdf">http://www.tga.gov.au/pdf/aadrb-0304.pdf</ext-link>. <access-date>Accessed September 14, 2012</access-date>.</citation>
</ref>
<ref id="bibr5-0009922812462235">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kovesi</surname><given-names>T</given-names></name>
<name><surname>Schuh</surname><given-names>S</given-names></name>
<name><surname>Spier</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Achieving control of asthma in preschoolers</article-title>. <source>CMAJ</source>. <year>2010</year>;<volume>182</volume>:<fpage>E172</fpage>-<lpage>E183</lpage>.</citation>
</ref>
<ref id="bibr6-0009922812462235">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holt</surname><given-names>S</given-names></name>
<name><surname>Suder</surname><given-names>A</given-names></name>
<name><surname>Weatherall</surname><given-names>M</given-names></name>
<name><surname>Cheng</surname><given-names>S</given-names></name>
<name><surname>Shirtcliffe</surname><given-names>P</given-names></name>
<name><surname>Beasley</surname><given-names>R</given-names></name>
</person-group>. <article-title>Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis</article-title>. <source>BMJ</source>. <year>2001</year>;<volume>323</volume>:<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr7-0009922812462235">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mortimer</surname><given-names>KJ</given-names></name>
<name><surname>Tata</surname><given-names>LJ</given-names></name>
<name><surname>Smith</surname><given-names>CJ</given-names></name>
<etal/></person-group>. <article-title>Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study</article-title>. <source>Thorax</source>. <year>2006</year>;<volume>61</volume>:<fpage>405</fpage>-<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr8-0009922812462235">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Masoli</surname><given-names>M</given-names></name>
<name><surname>Weatherall</surname><given-names>M</given-names></name>
<name><surname>Hold</surname><given-names>S</given-names></name>
<name><surname>Beasley</surname><given-names>R</given-names></name>
</person-group>. <article-title>Clinical dose-response relationship of fluticasone propionate in adults with asthma</article-title>. <source>Thorax</source>. <year>2004</year>;<volume>59</volume>:<fpage>16</fpage>-<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr9-0009922812462235">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pedersen</surname><given-names>S</given-names></name>
</person-group>. <article-title>Clinical safety of inhaled corticosteroids for asthma in children</article-title>. <source>Drug Saf</source>. <year>2006</year>;<volume>29</volume>:<fpage>599</fpage>-<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr10-0009922812462235">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>M</given-names></name>
<name><surname>Crisalida</surname><given-names>T</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Economides</surname><given-names>A</given-names></name>
<name><surname>Kaliner</surname><given-names>M</given-names></name>
</person-group>. <article-title>Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma</article-title>. <source>Ann Allergy Immunol</source>. <year>2006</year>;<volume>96</volume>:<fpage>437</fpage>-<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr11-0009922812462235">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmet</surname><given-names>A</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Spier</surname><given-names>S</given-names></name>
</person-group>. <article-title>Adrenal suppression: a practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy</article-title>. <source>Allergy Asthma Clin Immunol</source>. <year>2011</year>;<volume>7</volume>:<fpage>13</fpage>.</citation>
</ref>
<ref id="bibr12-0009922812462235">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shulman</surname><given-names>DI</given-names></name>
<name><surname>Palmert</surname><given-names>MR</given-names></name>
<name><surname>Kemp</surname><given-names>SF</given-names></name>
</person-group>. <article-title>Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood</article-title>. <source>Pediatrics</source>. <year>2007</year>;<volume>119</volume>:<fpage>e484</fpage>-<lpage>e494</lpage>. doi:<pub-id pub-id-type="doi">10.1542/peds.2006-1612</pub-id>.</citation>
</ref>
<ref id="bibr13-0009922812462235">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donaldson</surname><given-names>MD</given-names></name>
<name><surname>Morrison</surname><given-names>C</given-names></name>
<name><surname>Lees</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Fatal and near-fatal encephalopathy With hyponatremia in two siblings with fluticasone-induced adrenal suppression</article-title>. <source>Acta Paediatr</source>. <year>2007</year>;<volume>96</volume>:<fpage>768</fpage>-<lpage>772</lpage>.</citation>
</ref>
<ref id="bibr14-0009922812462235">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Todd</surname><given-names>GR</given-names></name>
<name><surname>Acerini</surname><given-names>CL</given-names></name>
<name><surname>Ross-Russell</surname><given-names>R</given-names></name>
<name><surname>Zahra</surname><given-names>S</given-names></name>
<name><surname>Warner</surname><given-names>JT</given-names></name>
<name><surname>McCance</surname><given-names>D</given-names></name>
</person-group>. <article-title>Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom</article-title>. <source>Arch Dis Child</source>. <year>2002</year>;<volume>87</volume>:<fpage>457</fpage>-<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr15-0009922812462235">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caballero</surname><given-names>F</given-names></name>
<name><surname>Gunzler</surname><given-names>P</given-names></name>
</person-group>. <article-title>Severe adrenal suppression in a 12 year old induced by beclomethasone dipropionate</article-title>. <source>J Allergy Clin Immunol</source>. <year>1993</year>;<volume>91</volume>:<fpage>261</fpage>.</citation>
</ref>
<ref id="bibr16-0009922812462235">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kannisto</surname><given-names>S</given-names></name>
<name><surname>Korppi</surname><given-names>M</given-names></name>
<name><surname>Remes</surname><given-names>K</given-names></name>
<name><surname>Voutilainen</surname><given-names>R</given-names></name>
</person-group>. <article-title>Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2000</year>;<volume>85</volume>:<fpage>652</fpage>-<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr17-0009922812462235">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barton</surname><given-names>K</given-names></name>
</person-group>. <article-title>Fluticasone and adrenal suppression</article-title>. <source>Can Adverse React Newslett</source>. <year>2003</year>;<volume>13</volume>:<fpage>2</fpage>.</citation>
</ref>
<ref id="bibr18-0009922812462235">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carlsen</surname><given-names>K-H</given-names></name>
<name><surname>Gerritsen</surname><given-names>J</given-names></name>
</person-group>. <article-title>Inhaled steroids in children: adrenal suppression and growth impairment</article-title>. <source>Eur Respir J</source>. <year>2002</year>;<volume>19</volume>:<fpage>985</fpage>-<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr19-0009922812462235">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szefler</surname><given-names>SJ</given-names></name>
<name><surname>Martin</surname><given-names>RJ</given-names></name>
<name><surname>King</surname><given-names>TS</given-names></name>
<etal/></person-group>. <article-title>Significant variability in response to inhaled corticosteroids for persistent asthma; Asthma Clinical Research Network of the National Heart Lung, and Blood Institute</article-title>. <source>J Allergy Clin Immunol</source>. <year>2002</year>;<volume>109</volume>:<fpage>410</fpage>-<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr20-0009922812462235">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Todd</surname><given-names>GR</given-names></name>
</person-group>. <article-title>Goal—asthma control, but at what cost?</article-title> <source>Am J Respir Crit Care Med</source>. <year>2005</year>;<volume>172</volume>:<fpage>154</fpage>-<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr21-0009922812462235">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>L</given-names></name>
<name><surname>Clayton</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Adrenal insufficiency after treatment with fluticasone. Lowest possible dose of inhaled glucocorticoids should be given</article-title>. <source>BMJ</source>. <year>2002</year>;<volume>325</volume>:<fpage>836</fpage>.</citation>
</ref>
<ref id="bibr22-0009922812462235">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paton</surname><given-names>J</given-names></name>
<name><surname>Jardine</surname><given-names>E</given-names></name>
<name><surname>McNeill</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone</article-title>. <source>Arch Dis Child</source>. <year>2006</year>;<volume>91</volume>:<fpage>808</fpage>-<lpage>813</lpage>.</citation>
</ref>
<ref id="bibr23-0009922812462235">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zimmerman</surname><given-names>B</given-names></name>
<name><surname>Gold</surname><given-names>M</given-names></name>
<name><surname>Wherrett</surname><given-names>D</given-names></name>
<name><surname>Hanna</surname><given-names>AK</given-names></name>
</person-group>. <article-title>Adrenal suppression in two patients with asthma treated with low dose of the inhaled steroid fluticasone propionate</article-title>. <source>J Allergy Clin Immunol</source>. <year>1998</year>;<volume>101</volume>:<fpage>425</fpage>-<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr24-0009922812462235">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Todd</surname><given-names>GR</given-names></name>
<name><surname>Wright</surname><given-names>D</given-names></name>
<name><surname>Ryan</surname><given-names>M</given-names></name>
</person-group>. <article-title>Acute adrenal insufficiency in a patient with asthma after changing from fluticasone propionate to budesonide</article-title>. <source>J Allergy Clin Immunol</source>. <year>1999</year>;<volume>103</volume>(<issue>9</issue> <supplement>pt 1</supplement>):<fpage>956</fpage>-<lpage>957</lpage>.</citation>
</ref>
<ref id="bibr25-0009922812462235">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García García</surname><given-names>E</given-names></name>
<name><surname>López Siguero</surname><given-names>JP</given-names></name>
<name><surname>Pérez Frías</surname><given-names>J</given-names></name>
<name><surname>Pérez Ruiz</surname><given-names>E</given-names></name>
<name><surname>Martínez Valverde</surname><given-names>A</given-names></name>
</person-group>. <article-title>Adrenocortical suppression after high doses of inhaled fluticasone [in Spanish]</article-title>. <source>Ann Esp Pediatr</source> <year>2000</year>;<volume>52</volume>:<fpage>476</fpage>-<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr26-0009922812462235">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>L</given-names></name>
<name><surname>Wales</surname><given-names>JK</given-names></name>
<name><surname>Kibirige</surname><given-names>MS</given-names></name>
<name><surname>Massarano</surname><given-names>AA</given-names></name>
<name><surname>Couriel</surname><given-names>JM</given-names></name>
<name><surname>Clayton</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Symptomatic adrenal insufficiency during inhaled corticosteroid treatment</article-title>. <source>Arch Dis Child</source>. <year>2001</year>;<volume>85</volume>:<fpage>330</fpage>-<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr27-0009922812462235">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Todd</surname><given-names>GR</given-names></name>
<name><surname>Buck</surname><given-names>J</given-names></name>
<name><surname>Ross-Russell</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate</article-title>. <source>Chest</source>. <year>2001</year>;<volume>120</volume>:<fpage>139S</fpage>.</citation>
</ref>
<ref id="bibr28-0009922812462235">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drake</surname><given-names>AJ</given-names></name>
<name><surname>Howells</surname><given-names>RJ</given-names></name>
<name><surname>Shield</surname><given-names>JP</given-names></name>
<name><surname>Prendiville</surname><given-names>A</given-names></name>
<name><surname>Ward</surname><given-names>PS</given-names></name>
<name><surname>Crowne</surname><given-names>EC</given-names></name>
</person-group>. <article-title>Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate</article-title> <source>BMJ</source>. <year>2002</year>;<volume>324</volume>:<fpage>1081</fpage>-<lpage>1083</lpage>.</citation>
</ref>
<ref id="bibr29-0009922812462235">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Todd</surname><given-names>GR</given-names></name>
<name><surname>Acerini</surname><given-names>CL</given-names></name>
<name><surname>Ross-Russell</surname><given-names>R</given-names></name>
<name><surname>Zahra</surname><given-names>S</given-names></name>
<name><surname>Warner</surname><given-names>JT</given-names></name>
<name><surname>McCance</surname><given-names>D</given-names></name>
</person-group>. <article-title>Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom</article-title>. <source>Arch Dis Child</source>. <year>2002</year>;<volume>87</volume>:<fpage>457</fpage>-<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr30-0009922812462235">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Russell</surname><given-names>G</given-names></name>
</person-group>. <article-title>Inhaled corticosteroids and adrenal insufficiency</article-title>. <source>Arch Dis Child</source>. <year>2002</year>;<volume>87</volume>:<fpage>455</fpage>-<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr31-0009922812462235">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perry</surname><given-names>RJ</given-names></name>
<name><surname>Findlay</surname><given-names>CA</given-names></name>
<name><surname>Donaldson</surname><given-names>MDC</given-names></name>
</person-group>. <article-title>Cushing syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids</article-title>. <source>Arch Dis Child</source>. <year>2002</year>;<volume>87</volume>:<fpage>45</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr32-0009922812462235">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipworth</surname><given-names>BJ</given-names></name>
</person-group>. <article-title>Adrenal insufficiency after treatment with fluticasone. Second line controller treatment might have been tried</article-title>. <source>BMJ</source>. <year>2002</year>;<volume>325</volume>:<fpage>836</fpage>.</citation>
</ref>
<ref id="bibr33-0009922812462235">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sims</surname><given-names>D</given-names></name>
<name><surname>Griffiths</surname><given-names>A</given-names></name>
<name><surname>Armstrong</surname><given-names>D</given-names></name>
<name><surname>Clarke</surname><given-names>C</given-names></name>
<name><surname>Rodda</surname><given-names>C</given-names></name>
<name><surname>Freezer</surname><given-names>N</given-names></name>
</person-group>. <article-title>Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma</article-title>. <source>Eur Respir J</source>. <year>2003</year>;<volume>21</volume>:<fpage>633</fpage>-<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr34-0009922812462235">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>A</given-names></name>
<name><surname>Woodmansee</surname><given-names>DP</given-names></name>
</person-group>. <article-title>Adrenal Insufficiency from inhaled corticosteroids</article-title>. <source>Ann Intern Med</source>. <year>2004</year>;<volume>140</volume>:<fpage>W27</fpage>.</citation>
</ref>
<ref id="bibr35-0009922812462235">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eijkemans</surname><given-names>M</given-names></name>
<name><surname>Otten</surname><given-names>BJ</given-names></name>
<name><surname>Yntema</surname><given-names>JB</given-names></name>
</person-group>. <article-title>Adrenal cortex insufficiency in children due to inhaled corticosteroids [in Dutch]</article-title>. <source>Ned Tijdschr Geneeskd</source>. <year>2011</year>;<volume>155</volume>:<fpage>A2862</fpage>.</citation>
</ref>
<ref id="bibr36-0009922812462235">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dorsey</surname><given-names>MJ</given-names></name>
<name><surname>Cohen</surname><given-names>LE</given-names></name>
<name><surname>Phipatanakul</surname><given-names>W</given-names></name>
<name><surname>Denufrio</surname><given-names>D</given-names></name>
<name><surname>Schneider</surname><given-names>LC</given-names></name>
</person-group>. <article-title>Assessment of adrenal suppression in children with asthma treated with inhaled corticosteroids: use of dehydroepiandrosterone sulfate as a screening test</article-title>. <source>Ann Allergy Asthma Immunol</source>. <year>2006</year>;<volume>97</volume>:<fpage>182</fpage>-<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr37-0009922812462235">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Molimard</surname><given-names>M</given-names></name>
<name><surname>Girodet</surname><given-names>P-O</given-names></name>
<name><surname>Pollet</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation</article-title>. <source>Drug Saf</source>. <year>2008</year>;<volume>31</volume>:<fpage>769</fpage>-<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr38-0009922812462235">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heller</surname><given-names>MK</given-names></name>
<name><surname>Laks</surname><given-names>J</given-names></name>
<name><surname>Kovesi</surname><given-names>TA</given-names></name>
<name><surname>Ahmet</surname><given-names>A</given-names></name>
</person-group>. <article-title>Reversal of adrenal suppression with ciclesonide</article-title>. <source>J Asthma</source>. <year>2010</year>;<volume>47</volume>:<fpage>337</fpage>-<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr39-0009922812462235">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santiago</surname><given-names>AH</given-names></name>
<name><surname>Ratzan</surname><given-names>S</given-names></name>
</person-group>. <article-title>Acute adrenal crisis in an asthmatic child treated with inhaled fluticasone propionate</article-title>. <source>Int J Pediatr Endocrinol</source>. <year>2010</year>;<volume>2010</volume>:<fpage>749239</fpage>.</citation>
</ref>
<ref id="bibr40-0009922812462235">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pearce</surname><given-names>L</given-names></name>
<name><surname>Mabin</surname><given-names>D</given-names></name>
</person-group>. <article-title>Inhaled corticosteroids and adrenal insufficiency</article-title>. <source>Arch Dis Child</source>. <year>2002</year>;<volume>87</volume>:E-letter.</citation>
</ref>
<ref id="bibr41-0009922812462235">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>RW</given-names></name>
<name><surname>Downey</surname><given-names>K</given-names></name>
<name><surname>Gordon</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Prevalence of hypothalamic-pituitary-adrenal suppression in children treated for asthma with inhaled corticosteroids</article-title>. <source>Paediatr Child Health</source>. <year>2012</year>;<volume>17</volume>:<fpage>e34</fpage>-<lpage>e39</lpage>.</citation>
</ref>
<ref id="bibr42-0009922812462235">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wade</surname><given-names>M</given-names></name>
<name><surname>Baid</surname><given-names>S</given-names></name>
<name><surname>Calis</surname><given-names>K</given-names></name>
<name><surname>Raff</surname><given-names>H</given-names></name>
<name><surname>Sinaii</surname><given-names>N</given-names></name>
<name><surname>Nieman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Technical details influence the diagnostic accuracy of the 1 microgram ACTH stimulation test</article-title>. <source>Eur J Endocrinol</source>. <year>2010</year>;<volume>162</volume>:<fpage>109</fpage>-<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.1530/EJE-09-0746</pub-id>.</citation>
</ref>
<ref id="bibr43-0009922812462235">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sahiner</surname><given-names>UM</given-names></name>
<name><surname>Cetinkaya</surname><given-names>S</given-names></name>
<name><surname>Ozmen</surname><given-names>S</given-names></name>
<name><surname>Arslan</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Evaluation of adrenocortical function in 3-7 aged asthmatic children treated with moderate doses of fluticasone propionate: reliability of dehydroepiandrosterone sulphate (DHEA-S) as a screening test</article-title>. <source>Allergol Immunopathol (Madr)</source>. <year>2011</year>;<volume>39</volume>:<fpage>154</fpage>-<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr44-0009922812462235">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pescollderungg</surname><given-names>L</given-names></name>
<name><surname>Radetti</surname><given-names>G</given-names></name>
<name><surname>Gottardi</surname><given-names>E</given-names></name>
<name><surname>Peroni</surname><given-names>DG</given-names></name>
<name><surname>Pietrobelli</surname><given-names>A</given-names></name>
<name><surname>Boner</surname><given-names>AL</given-names></name>
</person-group>. <article-title>Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test</article-title>. <source>Thorax</source>. <year>2003</year>;<volume>58</volume>:<fpage>227</fpage>-<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr45-0009922812462235">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>PM</given-names></name>
<name><surname>Clark</surname><given-names>H</given-names></name>
</person-group>. <article-title>Tests of adrenal insufficiency</article-title>. <source>Arch Dis Child</source>. <year>1999</year>;<volume>80</volume>:<fpage>330</fpage>-<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr46-0009922812462235">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maghnie</surname><given-names>M</given-names></name>
<name><surname>Uga</surname><given-names>E</given-names></name>
<name><surname>Temporini</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH, and CRH stimulation tests</article-title>. <source>Eur J Endocrinol</source>. <year>2005</year>;<volume>152</volume>:<fpage>735</fpage>-<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr47-0009922812462235">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaliner</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate</article-title>. <source>Clin Ther</source>. <year>2006</year>;<volume>28</volume>:<fpage>319</fpage>-<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr48-0009922812462235">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kazlauskaite</surname><given-names>R</given-names></name>
<name><surname>Evans</surname><given-names>AT</given-names></name>
<name><surname>Villabona</surname><given-names>CV</given-names></name>
<etal/></person-group>; <collab>Consortium for Evaluation of Corticotropin Test in Hypothalamic-Pituitary Adrenal Insufficiency</collab>. <article-title>Consortium for evaluation of corticortopin test in hypothalamic-pituitary insufficiency: a meta-analysis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>:<fpage>4245</fpage>-<lpage>4253</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>